Condition

Malignant Pleural Mesothelioma

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 82 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials82

Recruiting6

Common interventions25

Lead sponsors shown15

Clinical trials

60 shown

Hemithoracic Arc Radiotherapy Post Pleural DecorticationNCT06910449 · 2024-11-11

Hemithoracic Irradiation With Proton Therapy in Malignant Pleural MesotheliomaNCT05655078 · 2024-03-28

Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural MesotheliomaNCT06037941 · 2023-09-08

Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural MesotheliomaNCT05765084 · 2023-02-24

The IMmunotherapy Pleural 5-ALA PDTNCT04400539 · 2022-05-09

APG-2449 in Patients With Advanced Solid TumorsNCT03917043 · 2019-05-27

Comprehensive Oncogenomic Mapping and Exploration in Thoracic and Head & Neck OncologyNCT07550049 · 2026-04-01

NOT_YET_RECRUITING

OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint InhibitionNCT05425576 · 2025-06-01

NOT_YET_RECRUITING

Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural MesotheliomaNCT06318286 · 2024-03-13

ACTIVE_NOT_RECRUITING

Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable CancersNCT05582031 · 2023-04-30

Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural MesotheliomaNCT05660616 · 2023-04-01

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid TumorsNCT05795595 · 2023-03-13

AMT-151 in Patients With Selected Advanced Solid TumoursNCT05498597 · 2023-01-25

Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)NCT05308966 · 2022-05-03

Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including MesotheliomaNCT05278975 · 2022-03-31

Effect of HITHOC After Pleurectomy Decortication for Treatment of Malignant Pleural MesotheliomaNCT05508555 · 2022-03-01

A Study of Pembrolizumab and Radiation Therapy in People With MesotheliomaNCT04897022 · 2021-08-10

ACTIVE_NOT_RECRUITING

Real World Study of MPM in ChinaNCT05042557 · 2021-06-01

SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph IINCT04480372 · 2021-03-17

DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural MesotheliomaNCT04334759 · 2021-02-18

Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural MesotheliomaNCT04713761 · 2021-02-01

Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by ImmunotherapyNCT04775446 · 2020-11-26

Pembrolizumab + Defactinib In Pleural MesotheliomaNCT04201145 · 2020-09-01

Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural MesotheliomaNCT04525859 · 2020-08-19

A Study of Nivolumab and Chemotherapy Followed by Surgery for MesotheliomaNCT04162015 · 2019-11-12

ACTIVE_NOT_RECRUITING

MTG201 Plus Nivolumab in Patients With Relapsed Pleural MesotheliomaNCT04013334 · 2019-08-15

Effect of Expression of CD74 and VEGF on Outcome of Treatment in Patients With Malignant Pleural MesotheliomaNCT02761863 · 2019-07-30

Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural MesotheliomaNCT03710876 · 2019-01-21

Nintedanib as Switch Maintenance Treatment of Pleural Malignant MesotheliomaNCT02863055 · 2018-02-04

Autologous Dendritic Cell Vaccination in MesotheliomaNCT02649829 · 2017-10-03

Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural MesotheliomaNCT03269227 · 2017-08-14

ACTIVE_NOT_RECRUITING

MesoTRAP: A Study Comparing Video-assisted Thoracoscopic Partial Pleurectomy/Decortication With Indwelling Pleural Catheter in Patients With Trapped Lung Due to Malignant Pleural Mesothelioma.NCT03412357 · 2017-08-10

Clinical Study of YS110 in Patients With Malignant Pleural MesotheliomaNCT03177668 · 2017-08-08

Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)NCT03175172 · 2017-05-31

Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPMNCT02436733 · 2016-09-20

Ipilimumab and Nivolumab in the Treatment of Malignant Pleural MesotheliomaNCT03048474 · 2016-09-01

uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the LungNCT02755675 · 2016-04-01

Alvopem® (Pemetrexed) Safety AssessmentNCT04843007 · 2016-03-15

Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural MesotheliomaNCT02611037 · 2016-03-04

Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural MesotheliomaNCT02662504 · 2016-01-16

Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural MesotheliomaNCT02639767 · 2015-12-01

Nivolumab in Patients With Recurrent Malignant MesotheliomaNCT02497508 · 2015-07-01

Four Versus Six Cycles of Pemetrexed/Platinum for MPMNCT02497053 · 2015-06-01

Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural MesotheliomaNCT01722149 · 2015-02-19

A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural MesotheliomaNCT02347917 · 2015-02-01

Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)NCT02397928 · 2015-02-01

Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural MesotheliomaNCT01675765 · 2014-09-03

MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLCNCT02369198 · 2014-09-01

Effect of FAS and FAS Ligand Polymorphisms on Patients With Platinum-Based -Treated Malignant Pleural MesotheliomaNCT02269878 · 2014-04-01

Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma ParticipantsNCT02004028 · 2013-12-12

Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural MesotheliomaNCT01870609 · 2013-09-01

ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM)NCT02194231 · 2013-07-01

Study of the Combination of Tivantinib Plus Pemetrexed and CarboplatinNCT02049060 · 2013-01-01

Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma PatientsNCT01865045 · 2012-11-01

Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural MesotheliomaNCT01644994 · 2012-11-01

Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.NCT01721018 · 2012-10-01

A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural MesotheliomaNCT01486368 · 2012-06-26

Autologous Redirected RNA Meso-CIR T CellsNCT01355965 · 2011-05-01

A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural MesotheliomaNCT01279967 · 2011-01-01

Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality TherapyNCT01265433 · 2010-12-21

Common interventions

Leading sponsors

Ain Shams University5 Memorial Sloan Kettering Cancer Center5 Dana-Farber Cancer Institute3 The Netherlands Cancer Institute3 Aduro Biotech, Inc.2 AGC Biologics S.p.A.2 Armando Santoro, MD2 Copenhagen University Hospital, Rigshospitalet2 European Organisation for Research and Treatment of Cancer - EORTC2 University College, London2 University Hospital, Antwerp2 University Hospital, Lille2 University of Zurich2 Verastem, Inc.2 Abramson Cancer Center at Penn Medicine1

Trial status mix

COMPLETED47

UNKNOWN13

RECRUITING6

TERMINATED6

ACTIVE_NOT_RECRUITING4

WITHDRAWN4

NOT_YET_RECRUITING2

Phase mix

PHASE246

PHASE129

NA6

PHASE33

EARLY_PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.